{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P1Y", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "Division of Drug Information", "hasEmail": "mailto:druginfo@fda.hhs.gov"}, "description": "VANFLYTA (quizartinib) is an oral prescription tablet developed by Daiichi Sankyo Inc. for treating certain blood cancers. It works as a kinase inhibitor targeting FLT3 mutations, available in 17.7 mg and 26.5 mg strengths. This information was generated using AI and is provided for informational and research purposes only.", "distribution": [{"@type": "dcat:Distribution", "description": "\n        Access the FDA dataset for Quizartinib \u2014 ANDA 216993 submitted by Mylan Institutional LLC\n    ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216993", "mediaType": "text/html", "title": "Quizartinib"}], "identifier": "ANDA216993", "issued": "2016-09-16", "keyword": ["fda", "drug", "prescription-drugs", "health-care", "drug-safety"], "landingPage": "https://www.fda.gov/drugs", "license": "https://open.fda.gov/license", "modified": "2025-03-17", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Quizartinib"}